{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.0","upperLimit":"2.0","value":"1.0"},{"comment":"Not enough participants reached the threshold to support estimating the upper range.","groupId":"OG001","lowerLimit":"2.0","upperLimit":"NA","value":"4.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"144"},{"groupId":"OG001","value":"150"}],"units":"Participants"}],"description":"The Kaplan Meier estimate of median number of days (number of days at which 50% of participants have experienced the event, accounting for censored values) in each treatment arm to collect an optimum number of cells (≥6\\*10\\^6 CD34+ cells/kg) for transplantation.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of plerixafor. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of plerixafor for a maximum of 4 aphereses or until ≥ 6\\*10\\^6 CD34+ cells/kg were collected.","id":"OG000","title":"G-CSF Plus Plerixafor"},{"description":"Participants underwent mobilization with G-CSF for 4 days. On the evening of Day 4, participants received a dose of placebo. On each subsequent day, participants received a morning dose of G-CSF followed by apheresis and an evening dose of placebo for a maximum of 4 aphereses or until ≥ 6\\*10\\^6 CD34+ cells/kg were collected.","id":"OG001","title":"G-CSF Plus Placebo"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population","reportingStatus":"POSTED","timeFrame":"up to Day 8","title":"Median Number of Days to ≥6*10^6 CD34+ Cells/kg","type":"SECONDARY","unitOfMeasure":"Days"}